CN118159290A - 通过施用抗npr1抗体来影响血液动力学变化的方法 - Google Patents

通过施用抗npr1抗体来影响血液动力学变化的方法 Download PDF

Info

Publication number
CN118159290A
CN118159290A CN202280068577.9A CN202280068577A CN118159290A CN 118159290 A CN118159290 A CN 118159290A CN 202280068577 A CN202280068577 A CN 202280068577A CN 118159290 A CN118159290 A CN 118159290A
Authority
CN
China
Prior art keywords
antibody
subject
dose
binding fragment
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280068577.9A
Other languages
English (en)
Chinese (zh)
Inventor
M·邓恩
A·基思卡特
B·A·奥伦乔克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CN118159290A publication Critical patent/CN118159290A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280068577.9A 2021-10-11 2022-10-11 通过施用抗npr1抗体来影响血液动力学变化的方法 Pending CN118159290A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163254447P 2021-10-11 2021-10-11
US63/254,447 2021-10-11
PCT/US2022/077908 WO2023064769A1 (en) 2021-10-11 2022-10-11 Methods of effecting a hemodynamic change by administering an anti-npr1 antibody

Publications (1)

Publication Number Publication Date
CN118159290A true CN118159290A (zh) 2024-06-07

Family

ID=84045029

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280068577.9A Pending CN118159290A (zh) 2021-10-11 2022-10-11 通过施用抗npr1抗体来影响血液动力学变化的方法

Country Status (12)

Country Link
US (2) US20240327539A1 (enExample)
EP (1) EP4415820A1 (enExample)
JP (1) JP2024537284A (enExample)
KR (1) KR20240099275A (enExample)
CN (1) CN118159290A (enExample)
AU (1) AU2022363841A1 (enExample)
CA (1) CA3234238A1 (enExample)
CL (1) CL2024001071A1 (enExample)
CO (1) CO2024005662A2 (enExample)
IL (1) IL311917A (enExample)
MX (1) MX2024004302A (enExample)
WO (1) WO2023064769A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024542823A (ja) 2021-12-06 2024-11-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アンタゴニスト抗ｎｐｒ１抗体およびその使用方法
AU2024287056A1 (en) * 2023-06-08 2025-12-11 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-npr1 antibody and pharmaceutical use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
WO2010065293A1 (en) 2008-12-03 2010-06-10 Boehringer Ingelheim Pharmaceuticals Inc. Antibodies for guanylyl cyclase receptors
KR20210082207A (ko) 2018-10-23 2021-07-02 리제너론 파아마슈티컬스, 인크. 항-npr1 항체 및 이의 용도
US11066469B2 (en) * 2019-06-12 2021-07-20 Novartis Ag Natriuretic peptide receptor 1 antibodies and methods of use
US12325752B2 (en) * 2020-12-18 2025-06-10 Regeneron Pharmaceuticals, Inc. Immunoglobulin proteins that bind to NPR1 agonists

Also Published As

Publication number Publication date
JP2024537284A (ja) 2024-10-10
AU2022363841A1 (en) 2024-03-28
KR20240099275A (ko) 2024-06-28
EP4415820A1 (en) 2024-08-21
CA3234238A1 (en) 2023-04-20
US20240327539A1 (en) 2024-10-03
US20250034279A1 (en) 2025-01-30
CL2024001071A1 (es) 2024-12-06
IL311917A (en) 2024-06-01
CO2024005662A2 (es) 2024-05-10
WO2023064769A1 (en) 2023-04-20
MX2024004302A (es) 2024-06-19

Similar Documents

Publication Publication Date Title
ES3037632T3 (en) A leptin receptor agonist antibody for use in increasing bone mass in a subject suffering from metabolic dysfunction or hypoleptinemia
TW201945401A (zh) 降低心血管風險的方法
CN107922507B (zh) 抗pcsk9抑制性抗体用来治疗接受脂蛋白单采的高脂血症患者
US20250034279A1 (en) Methods of effecting a hemodynamic change by administering an anti-npr1 antibody
US20180008672A1 (en) Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
TW201609132A (zh) 使用ｐｃｓｋ９抑制劑之給藥療程
AU2019370295A1 (en) Subcutaneous dosage and administration of anti-C5 antibodies for treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
EP4245312A1 (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
KR20230009950A (ko) Ttr 아밀로이드증에 대한 조합 치료법
CA3153062A1 (en) Treatment of liver disease or disorder comprising actrii receptor antagonists
JP2026048712A (ja) 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン
KR20220035483A (ko) 항-pre-s1 hbv 항체를 이용한 hbv 감염 치료 방법
JP2026501550A (ja) リラキシン－２融合タンパク質類似体及びそれを使用する方法
JP7722991B2 (ja) 抗ｆｃｒｎ抗体を用いた温熱自己免疫性溶血性貧血の治療方法
KR20250107839A (ko) 심혈관계 질환의 치료 방법
US20240425574A1 (en) Anti-pdgf-b antibodies and pharmaceutical composition thereof
CA3040628A1 (en) Treatment regimens
CN115666578A (zh) 补体因子d抑制剂单独或结合抗c5抗体治疗阵发性睡眠性血红蛋白尿的用途
WO2021207667A1 (en) Compositions and methods for treating lung injury or acute respiratory distress syndrome (ards)
HK40099476A (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
CN118414354A (zh) 拮抗剂抗npr1抗体及其使用方法
HK40047010B (en) A leptin receptor agonist antibody for use in increasing bone mass in a subject suffering from metabolic dysfunction or hypoleptinemia
HK40047010A (en) A leptin receptor agonist antibody for use in increasing bone mass in a subject suffering from metabolic dysfunction or hypoleptinemia

Legal Events

Date Code Title Description
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination